Why the National Bio Innovation Committee Matters
In January 2026, the National Bio Innovation Committee was officially launched under presidential authority. Bio has been designated as Korea's third national strategic industry, targeting $50 billion in bio exports by 2030.
Five Core Policy Directions for 2026
1. Record Bio R&D Budget
2. Regulatory Fast-Track Expanded
3. Bio Innovation Zones in 5 Major Cities
4. Enhanced Global Clinical Trial Support
5. Bio Export One-Stop Center (Opening March 2026)
Action Plan for SME Bio Companies
KITIM Bio Policy Consulting
KITIM provides stage-specific consulting for SME bio companies—from R&D grant applications to regulatory fast-track navigation and global clinical trial funding.
